(NYSE) – PRNewswire
-
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Present
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
-
HUGOTON ROYALTY TRUST DECLARES NO DECEMBER CASH DISTRIBUTION
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Expos
-
HUGOTON ROYALTY TRUST DECLARES NO NOVEMBER CASH DISTRIBUTION
-
High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement
-
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
-
Actinium Appoints Lynn Bodarky as Chief Business Officer
-
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
-
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable
-
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
-
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting
-
Actinium Pharma Highlights Abstracts Accepted for Oral and Poster Presentation at the EANM 2023 Congress
-
Actinium Pharma to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit
-
HUGOTON ROYALTY TRUST DECLARES NO JULY CASH DISTRIBUTION
-
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress
-
Actinium Pharma Set to Join Russell 2000® and Russell 3000® Indexes
-
Actinium Pharma Announces Six Abstracts Accepted for Oral and Poster Presentation at the SNMMI 2023 Annual Meeting, Demonstrating Actinium's Leadership in Targeted Radiotherapy for Hematologic and Sol
-
HUGOTON ROYALTY TRUST DECLARES MAY CASH DISTRIBUTION
-
SEABOARD CORPORATION REPORT OF EARNINGS AND DIVIDEND DECLARATION
-
/C O R R E C T I O N -- Seaboard Corporation/
-
Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation at the European Society for Blood and Marrow Transplanta
-
Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones
-
Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting
-
Actinium Pharmaceuticals, Inc. to Present at Oppenheimer's 33rd Annual Healthcare Conference
-
HUGOTON ROYALTY TRUST ANNOUNCES RESULTS OF SPECIAL MEETING
-
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
-
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
-
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A
-
Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference
-
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones
-
Puxin Limited Announces First Quarter 2021 Unaudited Financial Results
Back to NYSE Stock Lookup
